| Name | Title | Contact Details |
|---|
Universal Hospital Services, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Minneapolis, MN. To find more information about Universal Hospital Services, Inc., please visit www.uhs.com
BluMetric is a new company built on a proud past. Its five originating operating companies, WESA, WESAtech, Envir-Eau, OEL-HydroSys, and Seprotech, are internationally known for cutting-edge work in the fields of water/wastewater treatment and professional environmental services. Our combined staff of approximately 170 scientists, engineers, industrial hygienists, environmental auditors, project managers, financial management specialists and support personnel are uniquely equipped to undertake environmental projects of any size, in any industry. Innovation, agility and client-responsive service are our hallmarks.
ConnectiCare is a leading health plan in the state of Connecticut. ConnectiCare has been dedicated to making Connecticut a healthier place to live and work since the company was founded in 1981. ConnectiCare has a full range of products and services for businesses, municipalities, individuals, and those who are Medicare-eligible. ConnectiCare is part of the EmblemHealth family of companies.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Kaiser Permanente is an American integrated managed care consortium, based in Oakland, California, United States, founded in 1945 by industrialist Henry J.